

New IQVIA Institute reports and COVID-19 resources now available

The COVID-19 pandemic is having a deep and lasting impact on healthcare systems around the world. At the IQVIA Institute we are leveraging a dynamic set of data assets and expertise to study and provide insights on how the entire healthcare ecosystem is adapting and changing, real-time and longer-term.

Here is a look at our latest resources

Institute Report

[Shifts in Healthcare Demand, Delivery and Care During the COVID-19 Era: Tracking the Impact in the United States](#)

The impact of COVID-19 is shifting weekly and even daily, across multiple dimensions. Our new report summarizes the various levels of impact in the United States. Areas covered in this report include a simulation of active COVID-19 cases nationally and for selected states, analysis on testing levels and mortality risks, the impact of COVID-19 on human behavior as it pertains to the use of health services, patient insurance coverage and out-of-pocket costs, overall medicine use and spending, care delivery for cancer patients, and COVID-19 therapeutics and vaccine research activity.

Data Science Simulator

[IQVIA COVID-19 Active Cases Curve Simulator](#)

This simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to support public health and private sector decisions based on the level and trajectory of active cases in a country, region or state. The simulator focuses on total active cases as a metric that speaks to the overall impact COVID-19 is having, not just limited to hospitalizations or deaths. The global and regional simulations in this report will be updated weekly.

Perspective

[COVID-19 as a Positive Turning Point in Healthcare: A Human Data Science Perspective](#)

COVID-19 is a pressure test of healthcare systems around the world. As we look to the future, we see ten areas of healthcare to rethink in order to not only be prepared for future disease outbreaks, but also to develop a better, more sustainable approach to human health. This is the first in a series of papers that will look at how Human Data Science can transform healthcare.

As the COVID-19 pandemic unfolds in real-time, we continue to deliver objective, relevant data and insights about changes in the broader health system.

Institute Reports

[2019 R&D Achievements: New Product Launches, Clinical Trial Activity and Investments](#)

This new report assesses the status of the research and development of medicines as of the end of 2019. While the analyses in this report were prepared prior to the outbreak of COVID-19, the practical ability to assess R&D productivity in a timely and granular way provides a unique window into life sciences innovation across the world. This report provides an essential baseline for assessing the impact of new R&D initiatives unleashed by the COVID-19 pandemic on existing clinical trial activity.

[The Global Use of Medicine Spending and Usage Trends: Outlook to 2024](#)

In this report you will find trends in medicine use and spending from 2009 to 2019 and an outlook to 2024. The measurement of medicine and spending is one of the key influencers of global health and will provide an important reference point as we assess the impact of COVID-19. As this report was prepared prior to the outbreak of COVID-19, the data will be updated in Q4 of this year to reflect the impact of COVID-19.

Our latest insights, data simulators, and reports are all available to download at iqviainstitute.org. Content will regularly be updated. As always, join the conversation about these topics and more on [LinkedIn](#) and [Twitter](#).

Regards,

Murray Aitken
Executive Director, IQVIA Institute
SVP, IQVIA